DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) announced today an alliance with AstraZeneca under which it will employ its novel and proprietary rabbit monoclonal antibody (RmAb) technologies to develop high specificity and high affinity RmAbs to AstraZeneca oncology targets. CST will apply its expertise and capabilities in assay development to perform rigorous validation of RmAbs for applications important to the advancement of AstraZeneca’s lead small molecule therapeutics. CST has recently developed and optimized proprietary technologies for producing RmAbs that show improved affinity, specificity and clone stability. AstraZeneca will benefit from CST’s RmAb capabilities through the alliance, in which CST will validate antibodies and immunoassays for monitoring target and small molecule activity.
